21 related articles for article (PubMed ID: 38563834)
1. Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Afghahi A; Purington N; Han SS; Desai M; Pierson E; Mathur MB; Seto T; Thompson CA; Rigdon J; Telli ML; Badve SS; Curtis CN; West RB; Horst K; Gomez SL; Ford JM; Sledge GW; Kurian AW
Clin Cancer Res; 2018 Jun; 24(12):2851-2858. PubMed ID: 29581131
[No Abstract] [Full Text] [Related]
2. Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development.
Gonçalves IV; Pinheiro-Rosa N; Torres L; Oliveira MA; Rapozo Guimarães G; Leite CDS; Ortega JM; Lopes MTP; Faria AMC; Martins MLB; Felicori LF
Sci Rep; 2024 May; 14(1):11576. PubMed ID: 38773133
[TBL] [Abstract][Full Text] [Related]
3. Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women.
Prasad S; Efird JT; James SE; Walker PR; Zagar TM; Biswas T
Springerplus; 2016; 5(1):756. PubMed ID: 27386241
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
6. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer.
Park JH; Lee HJ; Lee SB; Ahn JH; Kim JE; Jung KH; Gong G; Son BH; Ahn SH; Kim SB
Anticancer Res; 2019 Jun; 39(6):3111-3119. PubMed ID: 31177156
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
10. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Polley MC; Leon-Ferre RA; Leung S; Cheng A; Gao D; Sinnwell J; Liu H; Hillman DW; Eyman-Casey A; Gilbert JA; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari K; Couch F; Carter JM; Visscher DW; Nielsen TO; Goetz MP
Breast Cancer Res Treat; 2021 Feb; 185(3):557-566. PubMed ID: 33389409
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]